Abstract
Background: In Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown.
Methods: After the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data.
Results: Only 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases.
Conclusions: Even if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis.
Keywords: COVID-19; Cystic fibrosis; SARS-CoV-2; Seroprevalence.
【저자키워드】 COVID-19, SARS-CoV-2, cystic fibrosis, seroprevalence., 【초록키워드】 IgG, Hospitalized, lockdown, Seroprevalence, Diagnosis, fibrosis, virus, anti-SARS-CoV-2 antibodies, IgG antibody, IgG antibodies, anti-SARS-CoV-2 IgG antibodies, Patient, cystic fibrosis, molecular, respiratory, Belgium, COVID-19 symptoms, asymptomatic patients, asymptomatic patient, anti-SARS-CoV-2 IgM, respiratory symptoms, COVID-19 symptom, Government, Clinical data, one patient, difficulty, respiratory symptom, positive, risk of COVID-19, detect, collected, concerning, anti-SARS-CoV-2 IgG antibody, Clinique, Cystic, symptomatic patient, with COVID-19, 【제목키워드】 SARS-CoV-2 seroprevalence, cohort of patient,